Meeting
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
Authors
Ari David Baron
Sutter/California Pacific Medical Center, San Francisco, CA
Ari David Baron , Carlos López López , Stephen Lam Chang , Fabio Piscaglia , Zahra Ramji , Min Ren , Kasey Estenson , Arndt Vogel , Pierre Gholam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01761266
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4078)
DOI
10.1200/JCO.2023.41.16_suppl.4078
Abstract #
4078
Poster Bd #
399
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
First Author: Jasmine Huynh
Poster
2020 Gastrointestinal Cancers Symposium
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
First Author: Angel Alsina
Poster
2019 Gastrointestinal Cancers Symposium
Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.
First Author: Angel Alsina